ALDX

Aldeyra Therapeutics, Inc. [ALDX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ALDX Stock Summary

Top 10 Correlated ETFs

ALDX


Top 10 Correlated Stocks

ALDX


In the News

12:46 29 Mar 2024 ALDX

Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie

Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in cash at 12/31/23, burning $40M per year - plenty of cash to achieve monetization of reproxalap.

10:41 29 Mar 2024 ALDX

Here's Why You Should Invest in Aldeyra (ALDX) Stock Now

Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.

09:56 29 Mar 2024 ALDX

5 Small Drug Stocks to Buy From a Rebounding Industry

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

02:56 29 Mar 2024 ALDX

Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects

Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunctivitis. The company has an option agreement with AbbVie, indicating strategic M&A value and potential for a takeover. ALDX's current market cap of $181.76 million is mostly its cash value of $144.33 million, making it a strong buy with significant upside potential.

04:01 29 Mar 2024 ALDX

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis. The dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessib.

10:32 29 Mar 2024 ALDX

Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?

Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

01:32 29 Mar 2024 ALDX

BOX Gears Up to Report Q3 Earnings: What's in the Offing?

BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.

02:12 29 Mar 2024 ALDX

Invest In Penny Stocks? Is It Worth It & 4 To Watch Now

If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term instead of holding them forever.

02:11 29 Mar 2024 ALDX

5 Most Active Penny Stocks Today & Why They're Moving Now

Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.

10:47 29 Mar 2024 ALDX

Why Are Stocks Up Today?

Stocks are up today as investors prepare for the latest information from the Federal Reserve concerning interest rates. The Federal Open Market Committee (FOMC) meeting taking place today will result in an update to the interest rates that strongly affect the stock market.

ALDX Financial details

Company Rating
Neutral
Market Cap
170.8M
Income
-36.85M
Revenue
392.62K
Book val./share
2.02
Cash/share
2.41
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-4.5
Forward P/E
-6.93
PEG
1.1
P/S
-
P/B
1.62
P/C
1.35
P/FCF
-4.72
Quick Ratio
6.63
Current Ratio
6.81
Debt / Equity
0.13
LT Debt / Equity
0
-
-
EPS (TTM)
-0.62
EPS next Y
-0.47
EPS next Q
-0.11
EPS this Y
-39.05%
EPS next Y
-23.91%
EPS next 5Y
-233.81%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-42.64%
-
-
-
-
SMA20
-25%
SMA50
-
SMA100
50%
Inst Own
51.67%
Inst Trans
0.78%
ROA
-30%
ROE
-33%
ROC
-0.4%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
58.9M
Shs Float
56.55M
-
-
-
-
Target Price
-
52W Range
1.42-11.97
52W High
-70.37%
52W Low
+225.9%
RSI
48
Rel Volume
1.48
Avg Volume
538.98K
Volume
800.17K
Perf Week
11.61%
Perf Month
-9.47%
Perf Quarter
-44.57%
Perf Half Y
-47.01%
-
-
-
-
Beta
1.521
-
-
Volatility
0.13%, 0.43%
Prev Close
5.81%
Price
3.259
Change
10.47%

ALDX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.24-1.11-1.1-1.05-0.64
Operating cash flow per share
-1.66-1.1-0.79-0.97-0.51
Free cash flow per share
-1.66-1.1-0.79-0.97-0.51
Cash per share
2.712.294.252.982.42
Book value per share
1.771.753.812.592.03
Tangible book value per share
1.771.753.812.592.03
Share holders equity per share
1.771.753.812.592.03
Interest debt per share
0.570.510.330.30.3
Market cap
157.52M233.01M216.17M406.51M206.89M
Enterprise value
127.85M170.48M2.24M278.17M79.72M
P/E ratio
-2.59-6.2-3.65-6.62-5.51
Price to sales ratio
00000
POCF ratio
-3.5-6.21-5.08-7.18-6.82
PFCF ratio
-3.5-6.21-5.08-7.18-6.82
P/B Ratio
3.283.921.052.691.73
PTB ratio
3.283.921.052.691.73
EV to sales
00000
Enterprise value over EBITDA
-2.33-4.97-0.04-4.61-1.87
EV to operating cash flow
-2.84-4.55-0.05-4.91-2.63
EV to free cash flow
-2.84-4.55-0.05-4.91-2.63
Earnings yield
-0.39-0.16-0.27-0.15-0.18
Free cash flow yield
-0.29-0.16-0.2-0.14-0.15
Debt to equity
0.310.260.080.110.13
Debt to assets
0.20.180.070.090.11
Net debt to EBITDA
0.541.823.822.132.99
Current ratio
5.826.6919.7711.786.44
Interest coverage
-104.45-19.13-32.27-37-20.66
Income quality
0.7410.740.910.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.10-0.03-0.060
Stock based compensation to revenue
00000
Graham number
9.466.69.697.825.4
ROIC
-0.98-0.48-0.26-0.37-0.32
Return on tangible assets
-0.81-0.45-0.25-0.34-0.25
Graham Net
1.951.844.322.481.94
Working capital
62.26M70.65M220.98M165.66M121.09M
Tangible asset value
48.08M59.51M205.74M151.01M119.8M
Net current asset value
47.73M59.22M205.35M150.74M114.81M
Invested capital
0.310.260.080.110.13
Average receivables
14M26.5M75M64.12M1.62M
Average payables
1.93M594.97K700.67K576.66K735.84K
Average inventory
-14M-24.1M-72.6M-64.12M-1.62M
Days sales outstanding
00000
Days payables outstanding
3.06K2.48K1.41K188.531.86K
Days of inventory on hand
-106.12K-131.18K-172.7K-4.57K0
Receivables turnover
00000
Payables turnover
0.120.150.261.940.2
Inventory turnover
000-0.080
ROE
-1.27-0.63-0.29-0.41-0.31
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.01
Net income per share
-0.21-0.25-0.15-0.14-0.08
Operating cash flow per share
-0.19-0.16-0.23-0.140.01
Free cash flow per share
-0.19-0.16-0.23-0.140.01
Cash per share
2.982.812.582.432.41
Book value per share
2.592.332.212.092.02
Tangible book value per share
2.592.332.212.092.02
Share holders equity per share
2.592.332.212.092.02
Interest debt per share
0.280.280.280.280.27
Market cap
406.51M583.8M493.26M394.05M207.78M
Enterprise value
278.17M434.88M357.74M266.9M80.61M
P/E ratio
-8.39-9.78-13.72-12.03-10.93
Price to sales ratio
0000529.21
POCF ratio
-36.19-61.82-36.93-49.1415.19
PFCF ratio
-36.25-61.82-36.93-49.1415.19
P/B Ratio
2.694.253.83.21.73
PTB ratio
2.694.253.83.21.73
EV to sales
0000205.32
Enterprise value over EBITDA
-22.36-28.75-42.61-35.2-13.37
EV to operating cash flow
-24.77-46.05-26.78-33.26161.08
EV to free cash flow
-24.8-46.05-26.78-33.26161.08
Earnings yield
-0.03-0.03-0.02-0.02-0.02
Free cash flow yield
-0.03-0.02-0.03-0.020
Debt to equity
0.110.120.120.130.13
Debt to assets
0.090.10.10.110.11
Net debt to EBITDA
10.329.8516.1416.7721.08
Current ratio
11.7810.59.966.816.44
Interest coverage
-29.72-34.2-19.62-17.73-11.86
Income quality
0.870.61.490.98-0.11
Dividend Yield
00000.01
Payout ratio
0000-0.22
Sales general and administrative to revenue
00004.58
Research and developement to revenue
000010.95
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0.240000
Stock based compensation to revenue
0000-2.04
Graham number
3.473.652.762.551.91
ROIC
-0.08-0.1-0.09-0.08-0.02
Return on tangible assets
-0.07-0.09-0.06-0.06-0.03
Graham Net
2.482.282.142.021.93
Working capital
165.66M152.01M139.87M125.59M121.09M
Tangible asset value
151.01M137.24M129.88M123.01M119.8M
Net current asset value
150.74M137.04M129.75M122.94M114.81M
Invested capital
0.110.120.120.130.13
Average receivables
12.37M1.63M11.84K00
Average payables
720.28K281.66K350.25K259.01K792.63K
Average inventory
-12.37M-1.63M-11.84K00
Days sales outstanding
00000
Days payables outstanding
180.46577.43378.83342.271.81K
Days of inventory on hand
-4.38K-31.83000
Receivables turnover
00000
Payables turnover
0.50.160.240.260.05
Inventory turnover
-0.02-2.83000
ROE
-0.08-0.11-0.07-0.07-0.04
Capex per share
00000

ALDX Frequently Asked Questions

What is Aldeyra Therapeutics, Inc. stock symbol ?

Aldeyra Therapeutics, Inc. is a US stock , located in Lexington of Ma and trading under the symbol ALDX

What is Aldeyra Therapeutics, Inc. stock quote today ?

Aldeyra Therapeutics, Inc. stock price is $3.259 today.

Is Aldeyra Therapeutics, Inc. stock public?

Yes, Aldeyra Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap